Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Current Hematologic Malignancy Reports
Erschienen in: Current Hematologic Malignancy Reports 4/2011

01.12.2011 | Intermediate- and High-Grade Non-Hodgkin Lymphoma (Andre Goy, Section Editor)

Update: Peripheral T-Cell Lymphomas

verfasst von: Kerry J. Savage

Erschienen in: Current Hematologic Malignancy Reports | Ausgabe 4/2011

Einloggen, um Zugang zu erhalten

Abstract

Peripheral T-cell lymphomas (PTCLs) are a group of biologically heterogeneous but typically aggressive diseases. Progress in understanding and developing optimal therapies for PTCLs has been hampered by disease rarity and only relatively recent recognition of the importance of the T-cell phenotype. The International Peripheral T-cell Lymphoma Project was a large collaborative effort to provide a broader understanding of prognosis. Recently, several new therapies have shown promise in the treatment of PTCLs.
Literatur
1.
Harris N, Jaffe E, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood. 1994;84(5):1361–92.PubMed
2.
Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: International Agency for Research on Cancer; 2008.
3.
International T-Cell Lymphoma Project. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 2008;26(25):4124–30.CrossRef
4.
Dupuis J, Emile J, Mounier N, et al. Prognostic significance of Epstein-Barr virus in nodal peripheral T-cell lymphoma, unspecified: a Groupe d’Etude des Lymphomes de l’Adulte (GELA) study. Blood. 2006;108:4163–9.PubMedCrossRef
5.
•• Weisenburger DD, Savage KJ, Harris NL, et al. Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T-cell Lymphoma Project. Blood. 2011;117(12):3402–8. This evaluation of prognostic factors in PTCL-NOS comes from the International Peripheral T-Cell Lymphoma Project. PubMedCrossRef
6.
Zettl A, Rudiger T, Konrad MA, et al. Genomic profiling of peripheral T-cell lymphoma, unspecified, and anaplastic large T-cell lymphoma delineates novel recurrent chromosomal alterations. Am J Pathol. 2004;164(5):1837–48.PubMedCrossRef
7.
Thorns C, Bastian B, Pinkel D, et al. Chromosomal aberrations in angioimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma unspecified: a matrix-based CGH approach. Genes Chromosom Cancer. 2007;46(1):37–44.PubMedCrossRef
8.
de Leval L, Gaulard P. Pathology and biology of peripheral T-cell lymphomas. Histopathology. 2011;58(1):49–68.PubMedCrossRef
9.
Ballester B, Gisselbrecht C, Gaulard P, et al. Gene expression profiling identifies molecular subgroups among nodal peripheral T-cell lymphomas. Ann Oncol. 2005;16(Supp 5):124a.
10.
•• Iqbal J, Weisenburger DD, Greiner TC, et al. Molecular signatures to improve diagnosis in peripheral T-cell lymphoma and prognostication in angioimmunoblastic T-cell lymphoma. Blood. 2010;115(5):1026–36. This gene expression profiling study with a focus on AILT identifies molecular signatures associated with a favorable or unfavorable prognosis. PubMedCrossRef
11.
de Leval L, Rickman DS, Thielen C, et al. The gene expression profile of nodal peripheral T-cell lymphoma demonstrates a molecular link between angioimmunoblastic T-cell lymphoma (AITL) and follicular helper T (TFH) cells. Blood. 2007;109(11):4952–63.PubMedCrossRef
12.
Savage KJ, Chhanabhai M, Gascoyne RD, et al. Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification. Ann Oncol. 2004;15(10):1467–75.PubMedCrossRef
13.
Gallamini A, Stelitano C, Calvi R, et al. Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. Blood. 2004;103(7):2474–9.PubMedCrossRef
14.
Mourad N, Mounier N, Briere J, et al. Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d’Etude des Lymphomes de l’Adulte (GELA) trials. Blood. 2008;111(9):4463–70.PubMedCrossRef
15.
Morris SW, Kirstein MN, Valentine MB, et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin’s lymphoma. Science. 1994;1994:1281–4.CrossRef
16.
Mason D, Bastard C, Rimokh R, et al. CD30-positive large cell lymphomas (“Ki-1 lymphoma”) are associated with a chromosomal translocation involving 5q35. Br J Haematol. 1990;74:161–8.PubMedCrossRef
17.
Lamant L, de Reynies A, Duplantier MM, et al. Gene-expression profiling of systemic anaplastic large-cell lymphoma reveals differences based on ALK status and two distinct morphologic ALK+ subtypes. Blood. 2007;109(5):2156–64.PubMedCrossRef
18.
Merkel O, Hamacher F, Laimer D, et al. Identification of differential and functionally active miRNAs in both anaplastic lymphoma kinase (ALK)+ and ALK- anaplastic large-cell lymphoma. Proc Natl Acad Sci USA. 2010;107(37):16228–33.PubMedCrossRef
19.
• Sibon D, Fournier M, Briere J, et al. Prognostic factors and long term outcome of 138 adults with systemic anaplastic large-cell lymphoma: a retrospective study by the Groupe d’Etude Des Lymphomes De l’Adulte (GELA). Blood (ASH Annual Meeting Abstracts). 2010;116(21):322. This large study of ALCL patients identified the importance of age as well as ALK status for prognosis.
20.
Bonzheim I, Geissinger E, Roth S, et al. Anaplastic large cell lymphomas lack the expression of T-cell receptor molecules or molecules of proximal T-cell receptor signaling. Blood. 2004;104(10):3358–60.PubMedCrossRef
21.
Salaverria I, Bea S, Lopez-Guillermo A, et al. Genomic profiling reveals different genetic aberrations in systemic ALK-positive and ALK-negative anaplastic large cell lymphomas. Br J Haematol. 2008;140(5):516–26.PubMedCrossRef
22.
• Feldman AL, Dogan A, Smith DI, et al. Discovery of recurrent t(6;7)(p25.3;q32.3) translocations in ALK-negative anaplastic large cell lymphomas by massively parallel genomic sequencing. Blood. 2011;117(3):915–9. This article reports on a novel technique to discover recurrent translocation in ALK-negative ALCL. PubMedCrossRef
23.
Wada DA, Law ME, Hsi ED, et al. Specificity of IRF4 translocations for primary cutaneous anaplastic large cell lymphoma: a multicenter study of 204 skin biopsies. Mod Pathol. 2011;24(4):596–605.PubMedCrossRef
24.
ten Berge RL, de Bruin PC, Oudejans JJ, et al. ALK-negative anaplastic large-cell lymphoma demonstrates similar poor prognosis to peripheral T-cell lymphoma, unspecified. Histopathology. 2003;43(5):462–9.PubMedCrossRef
25.
Suzuki R, Kagami Y, Takeuchi K, et al. Prognostic significance of CD56 expression for ALK-positive and ALK- negative anaplastic large-cell lymphoma of T/null cell phenotype. Blood. 2000;96(9):2993–3000.PubMed
26.
Gascoyne R, Aoun P, Wu D, et al. Prognostic significance of anaplastic lymphoma kinase (ALK) protein expression in adults with anaplastic large cell lymphoma. Blood. 1999;93:3913–21.PubMed
27.
• Savage KJ, Harris NL, Vose JM, et al. ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. Blood. 2008;111(12):5496–504. This is a detailed study from the International Peripheral T-Cell Lymphoma Project regarding ALCL. PubMedCrossRef
28.
Popplewell L, Thomas SH, Huang Q, et al. Primary anaplastic large-cell lymphoma associated with breast implants. Leuk Lymphoma. 2011;52(8):1481–7.PubMedCrossRef
29.
Lazzeri D, Agostini T, Bocci G, et al. ALK-1-negative anaplastic large cell lymphoma associated with breast implants: a new clinical entity. Clin Breast Cancer. 2011 May 11 (Epub ahead of print).
30.
Kim B, Roth C, Young VL, et al. Anaplastic large cell lymphoma and breast implants: results from a structured expert consultation process. Plast Reconstr Surg. 2011 May 12 (Epub ahead of print).
31.
Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin’s lymphoma. N Engl J Med. 1993;328(14):1002–6.PubMedCrossRef
32.
Jiang L, Yuan CM, Hubacheck J, et al. Variable CD52 expression in mature T cell and NK cell malignancies: implications for alemtuzumab therapy. Br J Haematol. 2009;145(2):173–9.PubMedCrossRef
33.
Simon A, Peoch M, Casassus P, et al. Upfront VIP-reinforced-ABVD (VIP-rABVD) is not superior to CHOP/21 in newly diagnosed peripheral T cell lymphoma. Results of the randomized phase III trial GOELAMS-LTP95. Br J Haematol. 2010;151(2):159–66.PubMedCrossRef
34.
• Schmitz N, Trümper L, Ziepert M, et al. Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group. Blood. 2010;116(18):3418–25. This is a retrospective analysis of prospective studies evaluating the impact of etoposide on the outcome of PTCL. PubMedCrossRef
35.
Kluin-Nelemans HC, van Marwijk Kooy M, Lugtenburg PJ, et al. Intensified alemtuzumab-CHOP therapy for peripheral T-cell lymphoma. Ann Oncol. 2011;22(7):1595–600.PubMedCrossRef
36.
Kim JG, Sohn SK, Chae YS, et al. Alemtuzumab plus CHOP as front-line chemotherapy for patients with peripheral T-cell lymphomas: a phase II study. Cancer Chemother Pharmacol. 2007;60(1):129–34.PubMedCrossRef
37.
Foss FM, Sjak-Shie A, Goy A, et al. Phase II study of denileukin diftitox with CHOP chemotherapy in newly diagnosed PTCL: CONCEPT trial. J Clin Oncol. 2010;28(15s):8045a.
38.
Corazzelli G, Frigeri F, Marcacci G, et al. Gemcitabine, Ifosfamide, Oxaliplatin (GIFOX) as first-line treatment in high-risk peripheral T-Cell/NK lymphomas: a phase II trial. Blood (ASH Annual Meeting Abstracts). 2010;116(21):2829.
39.
Mahadevan D, Unger JM, Persky DO, et al. Phase II trial of Cisplatin plus Etoposide plus Gemcitabine plus Solumedrol (PEGS) in peripheral T-cell non-Hodgkin lymphoma (SWOG S0350). Ann Oncol. 2011;22(Suppl 4 111a):5–282.
40.
• Jaccard A, Gachard N, Marin B, et al. Efficacy of L-asparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK/T-cell lymphoma, a phase 2 study. Blood. 2011;117(6):1834–9. This is a report of a promising new L-asparaginase combination for extranodal NK/T-cell lymphoma. PubMedCrossRef
41.
Escalon MP, Liu NS, Yang Y, et al. Prognostic factors and treatment of patients with T-cell non-Hodgkin lymphoma. Cancer. 2005;103(10):2091–8.PubMedCrossRef
42.
• d’Amore F, Relander T, Lauritzsen GF, et al. Dose-dense induction followed by autologous stem cell transplant (ASCT) leads to sustained remissions in a large fraction of patients with previously untreated peripheral T-cell lymphomas (PTCLs)—overall and subtype-specific results of a phase II study from Nordic Lymphoma Group. Haematologica. 2009;94(supplement 2):437. These are preliminary results of large phase II prospective study of ASCT in untreated PTCLs.
43.
Relander T, Lauritzsen GF, Jantunen E, et al. Favorable outcome in ALK-negative anaplastic large-cell lymphoma following intensive induction chemotherapy and Autologous Stem Cell Transplantation (ASCT): a prospective study by the Nordic Lymphoma Group (NLG-T-01). Blood (ASH Annual Meeting Abstracts). 2010;116(21):3566.
44.
45.
• Le Gouill S, Milpied N, Buzyn A, et al. Graft-versus-lymphoma effect for aggressive T-cell lymphomas in adults: a study by the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire. J Clin Oncol. 2008;26(14):2264–71. This is the largest study evaluating the outcome of PTCL patients treated with allogeneic transplantation. PubMedCrossRef
46.
Jacobsen ED, Kim HT, Ho VT, et al. A large single-center experience with allogeneic stem-cell transplantation for peripheral T-cell non-Hodgkin lymphoma and advanced mycosis fungoides/Sezary syndrome. Ann Oncol. 2011;22(7):1608–13.PubMedCrossRef
47.
O’Connor OA, Horwitz S, Hamlin P, et al. Phase II-I-II study of two different doses and schedules of pralatrexate, a high-affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies. J Clin Oncol. 2009;27(26):4357–64.PubMedCrossRef
48.
• O’Connor OA, Pro B, Pinter-Brown L, et al. Pralatrexate in patients with relapsed or refractory peripheral t-cell lymphoma: results from the pivotal PROPEL study. J Clin Oncol. 2011;29(9):1182–9. This is the first study evaluating a novel agent specifically in relapsed/refractory PTCL. PubMedCrossRef
49.
• Piekarz RL, Frye R, Prince HM, et al. Phase II trial of romidepsin in patients with peripheral T-cell lymphoma. Blood. 2011;117(22):5827–34. This phase II study evaluates romidepsin in relapsed/refractory PTCL. PubMedCrossRef
50.
Coiffier B, Pro B, Prince HM, et al. Final results from a pivotal, multicenter, international, open-label, phase 2 study of romidepsin in progressive or relapsed Peripheral T-Cell Lymphoma (PTCL) following prior systemic therapy. Blood (ASH Annual Meeting Abstracts). 2010;116(21):114.
51.
Pohlman B, Advani R, Duvic M, et al. Final results of a phase II trial of belinostat (PXD101) in patients with recurrent or refractory peripheral or cutaneous T-cell lymphoma. Blood (ASH Annual Meeting Abstracts). 2009;114(22):920.
52.
Forero-Torres A, Bernstein S, Gopal A, et al. SGN-30 (anti-CD30 monoclonal antibody) is active and well tolerated in patients with refractory or recurrent systemic anaplastic large cell lymphoma. Blood. 2004;104(11):2637.
53.
• Shustov A, Advani R, Brice P, et al. Durable remissions with SGN-et (brentuximab vedotin): updated results of a phase 2 study in patients with relapsed or refractory systemic anaplastic large cell lymphoma (sALCL). Ann Oncol. 2011;22(Supp 4):5–282. This phase II study evaluated brentuximab vedotin in relapsed/refractory ALCL.
54.
Evens AM, Gordon LI, Patton D, et al. Phase I results of combination gemcitabine and bortezomib (Velcade(R)) for relapsed/refractory nodal T-cell Non-Hodgkin Lymphoma (T-NHL) and Aggressive B-Cell NHL (B-NHL). Blood (ASH Annual Meeting Abstracts). 2008;112(11):2005.
55.
O’Connor OA. Novel agents in development for peripheral T-cell lymphoma. Semin Hematol. 2010;47 Suppl 1:S11–4.PubMedCrossRef
56.
Kim SJ, Eom H-S, Kim JS, et al. The efficacy of Bortezomib-CHOP in patients with advanced stage T or NK/T cell lymphomas: the results of multicenter phase II study [abstract]. ASH Annu Meet Abstracts. 2010;116(21):1791.
57.
Delmer A, Fitoussi P, Gaulard P, et al. A phase II study of bortezomib in combination with intensified CHOP-like regimen (ACVBP) in patients with previously untreated T-cell lymphoma: Results of the GELA LNH05–1 T trial. J Clin Oncol. 2009;27(15S):8554a.
58.
Dueck G, Chua N, Prasad A, et al. Interim report of a phase 2 clinical trial of lenalidomide for T-cell non-Hodgkin lymphoma. Cancer. 2010;116(19):4541–8.PubMedCrossRef
59.
Zinzani PL, Pellegrini C, Broccoli A, et al. Lenalidomide monotherapy for relapsed/refractory peripheral T-cell lymphoma not otherwise specified. Leuk Lymphoma. 2011;52(8):1585–8.PubMedCrossRef
60.
O’Leary HM, Savage KJ. Update on the World Health Organization classification of peripheral T-cell lymphomas. Curr Hematol Malig Rep. 2009;4(4):227–35.PubMedCrossRef
Metadaten
Titel
Update: Peripheral T-Cell Lymphomas
verfasst von
Kerry J. Savage
Publikationsdatum
01.12.2011
Verlag
Current Science Inc.
Erschienen in
Current Hematologic Malignancy Reports / Ausgabe 4/2011
Print ISSN: 1558-8211
Elektronische ISSN: 1558-822X
DOI
https://doi.org/10.1007/s11899-011-0100-3

Weitere Artikel der Ausgabe 4/2011

Current Hematologic Malignancy Reports 4/2011 Zur Ausgabe

Low-Grade Non-Hodgkin Lymphoma (Peter McLaughlin, Section Editor)

Recent Developments in Nongastric Mucosa-Associated Lymphoid Tissue Lymphoma

T-Cell and Other Lymphoproliferative Malignancies (Claire Dearden, Section Editor)

PET in T-Cell Lymphoma

T-Cell and Other Lymphoproliferative Malignancies (Claire Dearden, Section Editor)

CD30+ Neoplasms of the Skin

T-Cell and Other Lymphoproliferative Malignancies (Claire Dearden, Section Editor)

Enteropathy-Associated T-Cell Lymphoma: Epidemiology, Clinical Features, and Current Treatment Strategies

Low-Grade Non-Hodgkin Lymphoma (Peter McLaughlin, Section Editor)

Rituximab Maintenance Versus Radioimmunotherapy Consolidation in Follicular Lymphoma: Which, When, and for Whom?

Neu im Fachgebiet Onkologie

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

30.04.2024 Künstliche Intelligenz Nachrichten

Krebserkrankungen unbekannten Ursprungs (CUP) sind eine diagnostische Herausforderung. KI-Systeme können Pathologen dabei unterstützen, zytologische Bilder zu interpretieren, um den Primärtumor zu lokalisieren.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise